2q13 microdeletion syndrome: Report on a newborn with additional features expanding the phenotype by Piro E. et al.
Clin Case Rep. 2021;9:e04289.    |  1 of 5
https://doi.org/10.1002/ccr3.4289
wileyonlinelibrary.com/journal/ccr3
1 |  INTRODUCTION
In recent years, chromosomal microarray analysis (CMA) 
allowed the identification of a growing number of chromo-
somal imbalances within the human genome.1 The 2q13 
region contains clusters of highly homologous sequences, 
which facilitate the occurrence of deletions and/or dupli-
cations. A recurrent 1.71  Mb deletion is associated with a 
congenital syndrome (around 50 patients reported to date) 
manifesting with a variable phenotype (psychomotor devel-
opment disabilities, mild craniofacial dysmorphisms, and 
congenital heart disease), and currently defined as 2q13 dele-
tion or microdeletion syndrome. Hereby, we describe an ad-
ditional newborn with craniofacial dysmorphisms, congenital 
heart disease, hypotonia, and a 2q13 deletion of 1.7 Mb. The 
clinical and genomic findings observed are consistent with 
the diagnosis of 2q13 microdeletion syndrome. This new 
neonatal case report provides additional genotypic and clini-
cal data, as well as further insights into the possible biologi-
cal and molecular bases of the 2q13 microdeletion syndrome.
These copy number variations (CNVs, defined as a 
greater than 1  kb segment of DNA that has variable copy 
number as compared to normal reference genome) include 
deletions and duplications2 and involve single or multiple 
genes.1 CNVs may be either benign or associated with dis-
eases.2 Some regions of the genome are flanked by highly 
homologous sequences (segmental duplications, SDs, also 
known as low copy repeats).3 They are prone to mismatching 
and, then, to recurrent CNVs, some of which cause clini-
cally recognizable phenotypes (ie, Angelman, Prader- Willi, 
Smith- Magenis, and Williams- Beuren syndromes).1,4 The 
2q13 region contains clusters of such SDs, which facilitate 
recurrent deletions and/or duplications. These imbalances 
are less described than those affecting other chromosomes.4 
A recurrent pathogenic 1.71  Mb microdeletion is reported 
to date in around 50 patients.1 Their clinical phenotype is 
variable for the occurrence of mild (in the majority of cases) 
dysmorphic features, macro- or microcephaly, neurodevel-
opmental delay/behavior disorder (including hypotonia, im-
pairment in fine and global motor skills, autism spectrum 
disorder, attention deficit, and hyperactivity disorder), as 
well as congenital heart disease (CHD, the most frequent 
anomaly), and other congenital defects (ie, scoliosis, renal/
genital malformations).5
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We describe an additional newborn with craniofacial dysmorphisms, congenital 
heart disease, hypotonia, and a 2q13 deletion of 1.7 Mb. The clinical and genomic 
findings observed are consistent with the diagnosis of 2q13 microdeletion syndrome.
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Hereby, we describe an additional newborn with craniofa-
cial dysmorphisms, CHD, hypotonia, and a 2q13 deletion of 
1.7 Mb, whose diagnosis is consistent with 2q13 microdele-
tion syndrome. This new neonatal case report may provide 
additional genotypic and clinical data, as well as further in-
sights into the possible biological and molecular bases of the 
2q13 microdeletion syndrome.
2 |  PATIENT PRESENTATION
This newborn female was the first and only born by vagi-
nal delivery, from healthy nonconsanguineous parents, 
at 40+2  weeks of gestation after a naturally obtained and 
uneventful pregnancy. In the 26- year- old mother and 
25- year- old father, any disease, as well as history of use of 
drugs and/or exposition to radiation, also before conception, 
was ruled out. At birth, her weight was 3200  g (39th per-
centile), length 50 cm (55th percentile), and occipitofrontal 
circumference (OFC) 34.5  cm (64th percentile). She was 
transferred on the second day of life from a first level birth 
center of the town, because of feeding difficulties, hypotonia, 
and dysmorphic features. On admission to our department, 
she showed on physical examination: facial asymmetry for 
hypoplasia of the left side of the face, low hairline, broad 
nasal bridge, pear- shaped tip of the nose and short columella, 
and small chin (Figure 1A). Posteriorly rotated left ear with 
thick helix, homolateral preauricular tag, and pit (Figure 1B), 
as well as inferotemporal epibulbar dermoid of the left eye 
and absent uvula, were observed. A sacral dimple was also 
noted (Figure  2). Generalized hypotonia and feeding diffi-
culties completed her clinical profile. Brain ultrasound (US) 
showed a corpus callosum narrowing, between the anterior 
portion of the body and the genu. Abdomen and spinal cord 
US examinations showed no abnormalities. US heart evalu-
ation revealed a subaortic ventricular septal defect. A whole 
spine X- ray was also performed and found lumbar kyphosis 
without vertebral defects.
Array comparative genomic hybridization (a- CGH) anal-
ysis (100- 150  Kb resolution, genomic assembly GRCh37.
p13) identified a 2q13 deletion of 1.7 Mb and indicated the 
positions 111,399,243 and 113,098,686 as the breakpoints 
of the rearrangement. The deleted region involved differ-
ent genes, including partially BUB1, ACOXL, BCL2L11, 
MIR4435- 2HG, MIR4771- 2, ANAPC1, MERTK, TMEM87B, 
FBLN7, ZC3H8, and ZC3H6. a- CGH was also performed in 
both parents, showing normal results and, thus, confirming 
the de novo origin of the genomic abnormality.
The patient recovered from her initial feeding difficulties 
around the seventh day of life. Hearing screening through 
transient- evoked otoacoustic emissions (TEOAEs) revealed 
abnormal results. In order to ascertain and characterize the 
hearing loss, an audiological assessment was started. It in-
cluded to date auditory brainstem response (ABR), which 
showed a left unilateral moderately severe conductive hypoa-
cusis. She was discharged at 1 month of age after an otherwise 
uneventful clinical course and is included in a multidisci-
plinary (neurodevelopmental, surgical, audiologic, ophthal-
mologic, cardiologic) follow- up. She actually (3 months old) 
shows a mild developmental delay.
3 |  DISCUSSION
The cytogenetic band 2q13 is enriched in clusters of highly 
homologous sequences, which facilitate the occurrence of de-
letions and/or duplications, quite recurrent in size and break-
points.4 Among these rearrangements, a recurrent 1.71 Mb 
deletion is associated with a congenital syndrome (around 50 
patients reported to date) manifesting with variable pheno-
type, which includes psychomotor development disabilities, 
mild craniofacial dysmorphisms, and CHD, and currently de-
fined as 2q13 deletion or microdeletion syndrome.1,5
The phenotype of the present patient (showing craniofa-
cial dysmorphisms, CHD, and neurodevelopmental delay), 
although being overlapping with that of most 2q13 deletion 
subjects described to date, seems to be more severe (spe-
cifically for the eye and ear involvement), sharing clinical 
signs with the oculo- auriculo- vertebral spectrum (OAVS). 
This latter disorder affects craniofacial morphogenesis and 
F I G U R E  1  A, Note facial asymmetry 
for hypoplasia of the left side of the face, 
low hairline, broad nasal bridge, pear shaped 
tip of the nose, short columella, and small 
chin; B, the left ear is posteriorly rotated, 
with thick helix and preauricular tag and pit
(A) (B)
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involves structures derived from the first and second pha-
ryngeal arches.6 Its manifestations include asymmetric ear 
anomalies with or without hearing loss, hemifacial microso-
mia resulting in facial asymmetry, orofacial clefts, ocular (in-
cluding epibulbar dermoids), and vertebral defects. Cardiac, 
genitourinary, and cerebral malformations may be associated. 
Several chromosomal/genomic anomalies are observed in pa-
tients showing an OAVS phenotype. However, 2q13 deletions 
are not reported.7
The deleted region of our patient encompasses eleven 
genes, nine protein coding ones (BUB 1 partially deleted, 
ACOXL1, BCL211, MERTK, FBLN7, TMEM87B, ANAPC1, 
ZC3H8, and ZC3H6), and two coding for microRNA (miR-
NAs, MIR4435- 2HG, and MIR4771- 2).
The dysmorphism and head circumference anomaly gen-
erally observed in cases with this deletion may depend on 
FBLN7 (fibulin 7) haploinsufficiency. This gene encodes 
fibulin- 7, a glycoprotein which plays a role in the formation 
of facial bones.5 Its involvement may explain the hemifacial 
hypoplasia of our newborn, showing also absent uvula and 
small chin, as well as homolateral eye and ear involvement. 
Fibulin- 7 cooperates with other proteins involved in heart de-
velopment. Such function may clarify the association with 
CHDs reported in 2q13 deletion patients8 and observed also 
in our newborn. TMEM87B (transmembrane protein 87B) is 
likely related to developmental delays, autism spectrum dis-
orders (ASDs), and other psychiatric phenotypes as well as 
CHD, 5,8,9 and its defect may be consistent with the neuro-
logical (generalized hypotonia and feeding difficulties) and 
cardiac findings of our patient. Disruption of ACOXL (acyl- 
CoA oxidase like, affecting fatty acid metabolism) 1,2 and 
BCL2L11 (BCL2- like 11, which encodes an antiapoptotic 
protein expressed in the frontal cortex and in the cerebellum, 
thus increasing apoptosis and the correlated risk of ASDs) 
10 may contribute to neurodevelopmental and ASD pheno-
types of these subjects.1,2 ANAPC1 (anaphase promoting 
complex subunit 1), a neurodevelopmental facilitator mainly 
expressed in the brain and the lymphoid organs, and MERTK 
(MER proto- oncogene, tyrosine kinase) are candidate genes 
for the psychosis phenotype of 2q13 CNV carriers.1 The lat-
ter is also associated with retinal defects and autosomal re-
cessive retinitis pigmentosa. It may have, thus, a role in the 
ocular development, which is disrupted (epibulbar dermoid) 
in our patient.
In the rearranged DNA of our newborn, there are also two 
genes coding for miRNAs that may influence the expression 
of the phenotype. They are short (20- 24 nt) noncoding RNAs 
that are involved in post- transcriptional regulation gene ex-
pression. Between them, the MIR4435- 2HG gene is ubiqui-
tously expressed in different tissues, mainly brain, heart, and 
lymphoid organs. In the latter ones are also highly expressed 
ZC3H8 and ZC3H6 (zinc finger CCCH- type containing 8/6). 
Defects in one of these genes may cause a greater predis-
position to infections (including otitis) and contribute to the 
phenotype of our proband, as well as to that of 2q13 deletion 
patients, in which such risk is described.1
Several explanations for the variable expressivity 11 and 
reduced penetrance observed in 2q13 deletion patients are 
supposed, such as differences in gene content due to variable 
deletion breakpoints.4 Specifically, a more severe clinical 
expressivity (like that showed by our newborn, including 
craniofacial dysmorphisms, ocular involvement with epibul-
bar dermoid, and vertebral lumbar kyphosis) occurs because 
of the combined loss of more candidate genes present in the 
critical rearrangement.8 However, localization and width 
of such recurrent deletion is quite overlapping among the 
patients described in the literature. Therefore, besides the 
possible role played by genes contiguous to the deleted re-
gion (as occur in contiguous gene syndromes), there could 
be other plausible causes: In the “two hit” hypothesis, the 
2q13 deletion could represent a “first hit” (ie a risk factor) 
for a second one, represented by an additional genomic im-
balance (deletions and/or duplications), observed in some of 
the patients described to date,4 but which is absent in our 
proband; otherwise, other genomic mutations may unmask 
recessive alleles.
In the present patient, as whole genome sequencing was 
not performed, it cannot be ruled out that another genetic vari-
ant was contributing (or modify) to her phenotype. Moreover, 
epigenetic factors may also exacerbate the expressivity of 
the clinical picture.5 Our report is the first description of an 
OAVS phenotype in a 2q13 microdeletion patient. We can-
not establish to date whether such association is casual, or 
whether a genetic bond exists between them. In regard to this, 
it could be supposed that loss of FBLN7, which is expressed 
in the branchial arches,8 may be associated with development 
anomalies of the structures derived from the first and second 
pharyngeal arches (which are affected, indeed, in the OAVS).
Moreover, a further research on FBLN7 gene networks 
(https://genem ania.org/searc h/homo- sapie ns/FBLN7/, 
access 05/07/2020) identified a physical interaction 
F I G U R E  2  Sacral dimple
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network involving 3 genes (EDEM2, ASPH, and CLNS1A), 
a co- expression network involving 17 genes (GLYATL2, 
IZUMO2, SMYD2, BMPER, AHDC1, PRELID2, NEIL1, 
MDGA1, TLL1, TTC6, CDH7, EMID1, G6PC2, SH3GL3, 
AMBN, DOC2A, and BCL7A), and a shared protein domain 
network involving TLL1. Among the aforementioned genes, 
three are associated with clinical phenotypes overlapping 
with the 2q13 deletion syndrome: TLL1 (cardiac malforma-
tions), ADHC1 (hypotonia, corpus callosum hypoplasia), 
and ASPH (facial dysmorphism). No FBLN7 gene pathway 
has been described yet.
4 |  CONCLUSION
This study may provide useful data about the clinical and 
genomic features of 2q13 deletions and expand the phe-
notypes associated with this rearrangement, which does 
not have to date a recognizable set of specific manifesta-
tions.12 It strengthens the importance of microarray analy-
sis in cases of congenital malformations and/or dysmorphic 
features without a clinical picture suggestive for known 
disease.13- 15
The present report shows how an early genetic diagnosis, 
even more if obtained in neonatal age, may be crucial for the 
proper management of these patients. This must include indi-
vidualized follow- up, which may allow prevention of future 
comorbidities (eg, infections, hearing loss, orthopedic, and 
neuropsychiatric disorders), as well as genetic counseling for 
the family, including communication of recurrence risk for 
later pregnancies.16
Further studies are needed to widen the knowledge on 
the molecular bases of the disease. The awareness of the role 
played by each gene included within 2q13 region (functional 
studies, identification of single gene mutations),17 and the 
identification of further affected subjects, will allow its more 
precise genomic and clinical characterization,18 suggesting 
new elements of the genotype- phenotype correlations.19
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